PRMT5 is a major type II arginine methyltransferase that catalyzes sDMA on multiple substrates.[14] PRMT5 is brought to the forefront for its function in promoting tumor progression, and mounting evidence from mouse models demonstrates that PRMT5 inhibition can decrease the growth of many types of tumors including mantle cell lymphoma, acute myeloid lymphoma, chronic myeloid lymphoma, B‐cell lymphoma, glioma, and breast cancer.[15, 16]. Here, PRMT5 is linked to breast carcinoma.